TY - JOUR AU - Gomez, Rahul AU - Kafi, Aarya AU - Yung, Gordon AU - Aslam, Saima AU - Lin, Christine M. AU - Pollema, Travis AU - Golts, Eugene AU - Afshar, Kamyar PY - 2024 DA - 2024/04/28 TI - Low Mortality Associated with COVID-19 Infection in Lung Transplant Recipients at a Single Center JO - OBM Transplantation SP - 213 VL - 08 IS - 02 AB - Lung Transplant Recipients (LTR) are particularly vulnerable to severe infection, hospitalization, and death due to community acquired respiratory viruses. As a result, the global SARS-Cov-2 pandemic poses a higher risk to this population. We aim to study the lung function, severity of infection and mortality among LTR at a single center. A retrospective chart review was performed on all LTR at the University of San Diego, California Medical Center between June 2020 and September 2022. Spirometry was performed at 1-2 months and then again 3 months after infection. Patients were closely monitored for the development of acute cellular rejection (ACR). 72 LTR were infected with COVID-19. 37.5% required hospital admission, of which 25.9% required management in the intensive care unit (ICU). 73.6% LTR had received at least one vaccination dose prior to infection. Post-infection, the median drop in FEV1 was 140 mL and FVC was 25 mL within 1-2 months. At 3 months post-infection the median reduction in FVC was slightly larger at 75 ml, while median decline in FEV1 decreased to 55 ml. Overall, the rates of ACR and mortality in this population were both 4.2%. Additionally, monoclonal antibody (mAb) therapy reduced hospitalization (20.9% vs 62%) and mortality (0% vs 10.3%), Our study found low rates of ACR and mortality in LTR with confirmed COVID-19, despite the statistically significant decline in FEV1, and trends with FVC. The use of vaccinations and mAb therapy decreased rates of hospitalizations, with mAb therapy reducing mortality as well. SN - 2577-5820 UR - https://doi.org/10.21926/obm.transplant.2402213 DO - 10.21926/obm.transplant.2402213 ID - Gomez2024 ER -